Posted by Michael Wonder on 18 Sep 2020
Proposal to fund emicizumab for people with haemophilia A
18 September 2020 - PHARMAC is seeking feedback on a proposal to fund emicizumab (Hemlibra), a new treatment for people with haemophilia A, from 1 December 2020, through a provisional agreement with Roche.
From 1 December 2020, emicizumab (Hemlibra) would be funded for people with severe haemophilia A and inhibitors to a coagulation (clotting) factor (factor VIII) subject to certain clinical criteria.
Some people with haemophilia A have a greater tendency to spontaneously bleed and are considered to have more severe haemophilia A.
